AACR Abstract: First Evidence that Selective A2B Receptor Inhibition Lowers PD-L1 Tumor Expression and also Directly Suppresses Mesothelioma Tumor Growth

Core Insights - AlphaTON Capital Corp and its subsidiary Cyncado Therapeutics are presenting new findings on A2B receptor inhibition and its effects on PD-L1 expression in mesothelioma at the AACR-NCI-EORTC International Conference [1][2][4] Group 1: Research Findings - The research indicates that A2B receptor inhibition leads to a reduction in adenosine-mediated PD-L1 increase in a human mesothelioma cell line, correlating with decreased CREB phosphorylation [2] - In vivo studies show that TT-4 monotherapy outperforms anti-PD-1, and the combination of TT-4 with anti-PD-1 demonstrates significantly enhanced anti-tumor activity compared to either treatment alone, with increased T-cell infiltration observed [2][3] Group 2: Company Overview - AlphaTON Capital is a digital asset treasury company focused on managing a strategic reserve of TON tokens and developing the Telegram ecosystem, providing institutional-grade exposure to the TON ecosystem [5][6] - The company is involved in network validation, staking operations, and developing Telegram-based applications, with potential investments in decentralized finance protocols and gaming platforms [6] - Cyncado Therapeutics is developing small molecule adenosine receptor antagonists, with its lead program TT-4 targeting mesothelioma and expected to begin first-patient dosing in Q1 2026 [8]